NXD 1191
Alternative Names: NXD-1191; Spheron targeting drugLatest Information Update: 04 Nov 2017
At a glance
- Originator Nymox Pharmaceutical Corporation
- Class Antidementias
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Canada
- 25 Aug 2004 This compound is still in active development
- 02 Oct 2001 Preclinical development for Alzheimer's disease in Canada (unspecified route)